Given the current climate surrounding COVID-19, we will see a departure from the traditionally large conference setting. Unite Life Sciences brings you a new forum for driving transformational change in biopharma. Our forums set out to create a unique, intimate (and panel-free!) environment for stakeholders who want to engage with their industry colleagues outside of the traditional conference and trade show setting.
This fall, we are excited to bring you the Advanced Therapies Manufacturing Strategy Summit (ATMSS). ATMSS will engage industry stakeholders in a collaborative format to address strategic roadblocks in manufacturing Cell & Gene Therapies, like process improvement, cGMP standardization, and scalability via developmental think tanks, roundtable discussions, simulations, and work groups.
Take a look at the event program to see what we have in store for you as well as our early confirmed speakers, including: |
|
|
|
- Peter Marks MD, PhD, Director, Center for Biologics Evaluation and Research (CBER) FDA
- Laurie Smaldone MD, CMO/CSO, NDA Group
- Michael Lehmicke, Director, Science and Industry Affairs, Alliance for Regenerative Medicine
- Craig Malzahn, Vice President, Manufacturing and Supply Chain, REGENXBIO
- Mark Plavsic, CTO and Head of Nonclinical Development, LYSOGENE
|
|
|
|
Ahead of the fall event, we wanted to give the industry a virtual forum , live July 14-15, to asses the current manufacturing landscape in the context of the COVID-19 pandemic. What are the short and long term implications for advanced therapeutics development?
Register for free, and join advanced therapies stakeholders to take stock of the first half of 2020. Hear an update on FDA regulatory guidance for manufacturers, take part in a virtual Q&A, and gain insight on current consortia initiatives and priorities for cell and gene therapy manufacturing and commercial development.
| | |
|
|
|
|
